• Radiopharm Theranostics reported Phase 2b results for imaging agent RAD 101 in recurrent brain metastases, with the main study goal met.
• Results have already been presented, supporting the case that RAD 101 can align closely with standard imaging assessments.
• A Phase 3 multi-center registrational trial is planned to start in Q4 2026, supported by a manufacturing and distribution partnership with Siemens Healthineers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607310700PRIMZONEFULLFEED1001255403) on July 31, 2026, and is solely responsible for the information contained therein.